(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 1.69% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Novartis Ag's revenue in 2025 is $55,186,000,000.On average, 3 Wall Street analysts forecast NVS's revenue for 2025 to be $108,420,898,385,700, with the lowest NVS revenue forecast at $106,255,201,248,000, and the highest NVS revenue forecast at $112,210,571,700,000. On average, 3 Wall Street analysts forecast NVS's revenue for 2026 to be $111,039,208,943,400, with the lowest NVS revenue forecast at $106,759,967,814,000, and the highest NVS revenue forecast at $117,437,501,700,000.
In 2027, NVS is forecast to generate $112,098,779,282,700 in revenue, with the lowest revenue forecast at $107,069,131,044,000 and the highest revenue forecast at $115,124,101,200,000.